General Biotechnology

Sell the Line Before the Patent Breaks: A Business Development Guide for Solid Dose Equipment & Manufacturing Technology Suppliers Targeting Pre-LOE Generic Expansion

Sell the line before the patent breaks.
In pharma, timing isn’t just strategy—it’s survival. The market doesn’t wait for your sales cycle, your procurement lead times, or your customer’s internal approvals. By the time a patent cliff hits, the winner…

Sell the Line Before the Patent Breaks: A Business Development Guide for Solid Dose Equipment & Manufacturing Technology Suppliers Targeting Pre-LOE Generic Expansion Read Post »

General Biotechnology

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Most business development teams wait for the “cliff” to arrive—then scramble to win the scramble.
But in biologics, the cliff is predictab…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity Read Post »

General Biotechnology

Squeeze the Patent: How Drug Companies Use Reformulation and New Indications to Outlast Generic Competition

Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…

Squeeze the Patent: How Drug Companies Use Reformulation and New Indications to Outlast Generic Competition Read Post »

Biotechblog
Scroll to Top